Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.43 |
| ▸ | CDK4 | P11802 | 4/20 | 0.37 |
| ▸ | CCND1 | P24385 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3432890 | 0.79 | SLC6A2 (0.41) | SLC6A2CDK4CCND1SLC6A4DRD2 | |
| SCHEMBL28246061 | 0.69 | CDK4 (0.42) | SLC6A2CDK4CCND1SLC6A4DRD2 | |
| SCHEMBL29412428 | 0.68 | SLC6A2 (0.59) | SLC6A2CDK4CCND1SLC6A4 | |
| SCHEMBL704340 | 0.68 | SLC6A2 (0.59) | SLC6A2CDK4CCND1SLC6A4 | |
| SCHEMBL30416543 | 0.68 | NOTUM (0.48) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL17288078 | 0.68 | NOTUM (0.48) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL2556278 | 0.68 | CDK4 (0.41) | SLC6A2CDK4CCND1SLC6A4DRD2 | |
| SCHEMBL4782553 | 0.68 | CDK4 (0.35) | SLC6A2CDK4CCND1SLC6A4NOTUM | |
| SCHEMBL20037238 | 0.67 | SLC6A2 (0.57) | SLC6A2CDK4CCND1SLC6A4HTR2A | |
| SCHEMBL31280260 | 0.66 | SLC6A2 (0.56) | SLC6A2CDK4CCND1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678800-B2 | 2-(1H-indolylsulfanyl)-aryl amine derivatives for use in the treatment of affective disorders, pain, ADHD and stress urinary incontinence | H. LUNDBECK A/S (DK) | 2010-03-16 | — | — | US | disclosed |
| EP-1771415-B1 | 2- (1H-INDOLYLSULFANYL) -ARYL AMINE DERIVATIVES FOR USE IN THE TREATMENT OF AFFECTIVE DISORDERS, PAIN, ADHD AND STRESS URINARY INCONTINENCE | LUNDBECK & CO AS H (DK) | 2009-01-07 | — | — | EP | disclosed |
| US-20080027074-A1 | 2-(1H-Indolysulfanyl)-Aryl Amine Derivatives for Use in the Treatment of Affective Disorders, Pain, Adhd and Stress Urinary Incontinence | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | disclosed |
| EP-1771415-A1 | 2- (1H-INDOLYLSULFANYL) -ARYL AMINE DERIVATIVES FOR USE IN THE TREATMENT OF AFFECTIVE DISORDERS, PAIN, ADHD AND STRESS URINARY INCONTINENCE | H. Lundbeck A/S (DK) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006007843-A1 | 2-(1H-INDOLYLSULFANYL) -ARYL AMINE DERIVATIVES FOR USE IN THE TREATMENT OF AFFECTIVE DISORDERS, PAIN, ADHD AND STRESS URINARY INCONTINENCE | H. LUNDBECK A/S (DK) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027074-A1 | 2-(1H-Indolysulfanyl)-Aryl Amine Derivatives for Use in the Treatment of Affective Disorders, Pain, Adhd and Stress Urinary Incontinence | SLC6A2, HTR2C, SLC6A3 | SLC6A2 1/4885CDK4 3462/4885CCND1 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.